Stock Events

Teva- Pharmaceutical Industries 

€15.55
343
-€0.15-0.96% Friday 13:29

Statistics

Day High
15.7
Day Low
15.55
52W High
-
52W Low
-
Volume
0
Avg. Volume
-
Mkt Cap
17.49B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Dividends

0%Dividend Yield
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
N/A

Earnings

8MayConfirmed
Q3 2022
Q4 2022
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
0
0.33
0.67
1
Expected EPS
0.51
Actual EPS
0.48

People Also Follow

This list is based on the watchlists of people on Stock Events who follow TEV.F. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Novartis
NVS
Mkt Cap236.8B
Novartis, through its Sandoz division, is a leading competitor in the generic pharmaceuticals market, directly challenging Teva's product lineup.
Pfizer
PFE
Mkt Cap158.95B
Pfizer, with its Upjohn division now merged into Viatris, competes in both the generic and branded pharmaceutical markets, overlapping with Teva's business areas.
Abbvie
ABBV
Mkt Cap295.34B
AbbVie competes with Teva in the specialty pharmaceutical sector, particularly in areas like biosimilars and branded pharmaceuticals.
Johnson & Johnson
JNJ
Mkt Cap352.53B
Johnson & Johnson, through its Janssen Pharmaceuticals division, competes in the branded pharmaceutical market, particularly in areas where Teva also operates.
Merck &
MRK
Mkt Cap320.27B
Merck competes with Teva in the development and marketing of branded pharmaceuticals, especially in therapeutic areas where Teva is active.
Gilead Sciences
GILD
Mkt Cap83.09B
Gilead Sciences competes with Teva in the specialty pharmaceuticals market, particularly in the antiviral sector where Teva also has a presence.
AMGEN
AMGN
Mkt Cap166.77B
Amgen competes with Teva in the biopharmaceutical sector, particularly in the development of biosimilars, a growing area of Teva's business.
Sanofi
SNY
Mkt Cap125.78B
Sanofi competes with Teva in both the branded and generic pharmaceutical markets, with a broad product portfolio that overlaps with Teva's.
Astrazeneca
AZN
Mkt Cap239.79B
AstraZeneca competes with Teva in the branded pharmaceutical sector, particularly in areas like respiratory and cardiovascular diseases where Teva is also active.

About

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.
Show more...
CEO
Mr. Eliyahu Sharon Kalif
Employees
35001
Country
US
ISIN
US8816242098
WKN
000883035

Listings